Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand
Table 7
Frequency of common serious adverse events in both vaccine and placebo groups according to system organ class.